PT  - JOURNAL ARTICLE
AU  - Elena Riester
AU  - Beda Krieter
AU  - Peter Findeisen
AU  - Michael Laimighofer
AU  - Kathrin Schoenfeld
AU  - Tina Laengin
AU  - Christoph Niederhauser
TI  - Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts
AID  - 10.1101/2020.08.07.20169987
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.07.20169987
4099  - http://medrxiv.org/content/early/2020/08/07/2020.08.07.20169987.short
4100  - http://medrxiv.org/content/early/2020/08/07/2020.08.07.20169987.full
AB  - Background The Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics) was developed to provide an accurate and reliable method for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the specificity of the Elecsys Anti-SARS-CoV-2 immunoassay in prepandemic sample cohorts across five sites in Germany, Austria and Switzerland.Methods Specificity of the immunoassay was evaluated using anonymised, frozen, residual serum and/or plasma samples from blood donors or routine diagnostic testing. All samples were collected before September 2019 and therefore presumed negative for SARS-CoV-2-specific antibodies. Cohorts included samples from blood donors, pregnant women and paediatric patients. Point estimates and 95% confidence intervals (CIs) were calculated.Results Overall specificities for the Elecsys Anti-SARS-CoV-2 immunoassay in 9575 samples from blood donors (n = 6714) and diagnostic specimens (n = 2861) were 99.82% (95% CI 99.69-99.91) and 99.93% (95% CI 99.75-99.99), respectively. Among 2256 samples from pregnant women, specificity was 99.91% (95% CI 99.68-99.99). Among 205 paediatric samples, specificity was 100% (95% CI 98.22-100).Conclusion The Elecsys Anti-SARS-CoV-2 immunoassay demonstrated a very high specificity across blood donor samples and diagnostic specimens from Germany, Austria and Switzerland. Our findings support the use of the Elecsys Anti-SARS-CoV-2 immunoassay as a potential tool for determination of an immune response following previous exposure to SARS-CoV-2 in the general population, including in blood donors, pregnant women and paediatric populations.Competing Interest StatementElena Riester: received speaker's honorarium from Roche. Beda Krieter: no conflicts of interest to disclose. Peter Findeisen: no conflicts of interest to disclose. Michael Laimighofer: employee of Roche Diagnostics GmbH. Kathrin Schoenfeld: employee of Roche Diagnostics GmbH; owner of shares in Roche. Tina Laengin: employee of Roche Diagnostics GmbH. Christoph Niederhauser: no conflicts of interest to disclose.Funding StatementThis study was funded by Roche Diagnostics GmbH (Mannheim, Germany).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the study protocol provided by Roche Diagnostics and in accordance with the principles of the Declaration of Helsinki. All human samples utilised were anonymised, frozen, residual samples for which no ethical approval was required. The study protocol was submitted to institutional review boards at study sites in Innsbruck (Austria) and Bern (Switzerland) prior to study initiation; ethical approval was granted for Innsbruck, and a waiver granted for Bern.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm